PMID- 27915111
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20211204
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 45
DP  - 2017 Feb
TI  - Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients 
      with severely refractory epilepsies - A monocentric retrospective analysis of 
      systematically collected data from the German Kork Epilepsy Center.
PG  - 47-51
LID - S1059-1311(16)30238-2 [pii]
LID - 10.1016/j.seizure.2016.11.012 [doi]
AB  - PURPOSE: Perampanel (PER) and lacosamide (LCM) are antiepileptic drugs (AEDs) 
      approved for the adjunctive treatment of partial-onset seizures. At the time of 
      market entry, information on clinical effectiveness of new AEDs is limited to 
      results from pivotal trials, real-life or comparative data are missing. This 
      analysis of data collected retrospectively in a German epilepsy center used 
      unified evaluation criteria, and describes treatment outcomes with LCM and PER at 
      6 months. METHODS: Results of the first 70 consecutive patients who had received 
      LCM or PER after their market entries in Germany were compared. Outcome measures 
      comprised 50% responder rates, seizure freedom, retention, and incidence of 
      adverse events (AEs). RESULTS: The mean number of previous AEDs was 8.7 in the 
      PER group, and 7.3 in the LCM group. At 6 months, the 50% responder rate for all 
      seizures was 48.6% for PER, and 28.6% for LCM, with seizure freedom in 14.3% of 
      patients with PER, and 4.3% with LCM. Thirty-two AEs were reported for LCM, and 
      51 for PER, most commonly dizziness (22.9% of patients) for LCM, and 
      somnolence/tiredness for PER (41.4%). AEs were reported as primary reason for 
      discontinuation in 3 patients of the PER group. Retention rates were similar. 
      CONCLUSIONS: This analysis describes initial comparative benefits of two newly 
      available AEDs in two cohorts of patients with highly refractory epilepsies. 
      Responder and seizure freedom rates were numerically higher for PER. The analysis 
      suggests that new AEDs can provide a chance for seizure freedom in relevant 
      subgroups of patients, despite previous failure of multiple AEDs.
CI  - Copyright (c) 2016 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Kurth, Christoph
AU  - Kurth C
AD  - Kork Epilepsy Center, Landstrasse 1, 77694, Kehl-Kork, Germany.
FAU - Kockelmann, Edgar
AU  - Kockelmann E
AD  - Eisai GmbH, Lyoner Strasse 36, 60528, Frankfurt, Germany. Electronic address: 
      edgar_kockelmann@eisai.net.
FAU - Steinhoff, Bernhard J
AU  - Steinhoff BJ
AD  - Kork Epilepsy Center, Landstrasse 1, 77694, Kehl-Kork, Germany.
LA  - eng
PT  - Journal Article
DEP - 20161123
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - 563KS2PQY5 (Lacosamide)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Acetamides/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/*therapeutic use
MH  - Cohort Studies
MH  - Drug Resistant Epilepsy/*drug therapy
MH  - Female
MH  - Germany
MH  - Humans
MH  - Lacosamide
MH  - Male
MH  - Middle Aged
MH  - Nitriles
MH  - Pyridones/*therapeutic use
MH  - *Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Clinical practice
OT  - Epilepsy
OT  - Focal seizures
OT  - Lacosamide
OT  - Perampanel
OT  - Retrospective analysis
EDAT- 2016/12/05 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/12/05 06:00
PHST- 2016/09/28 00:00 [received]
PHST- 2016/11/14 00:00 [revised]
PHST- 2016/11/17 00:00 [accepted]
PHST- 2016/12/05 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/12/05 06:00 [entrez]
AID - S1059-1311(16)30238-2 [pii]
AID - 10.1016/j.seizure.2016.11.012 [doi]
PST - ppublish
SO  - Seizure. 2017 Feb;45:47-51. doi: 10.1016/j.seizure.2016.11.012. Epub 2016 Nov 23.